GLP-1 lawsuits and side effect disclosures: what's real?

What did @thelawyerangela actually say?

She listed seven side effects that plaintiffs allege drug makers failed to disclose: gastroparesis, bowel blockages, vision loss, pancreatitis, gallbladder disease, kidney damage, and muscle loss. She also cited "about 3,000" active lawsuits, claimed "a judge already said most of these can move forward," and stated that "nearly 500 deaths have been linked to these drugs" in FDA reports. Her framing throughout is legal, not medical. She's describing what people are suing over, not running a clinical trial. That distinction matters, and she does say it at the top. Credit where it's due.

The problem is that legal allegations and established science are two very different things, and a 110,000-view TikTok blurs that line fast. Some of her claims are well-supported by peer-reviewed research. Others are distorted, missing context, or presented in a way that would reasonably terrify someone who just started a GLP-1 medication.

Does the science back this up?

Partially, yes. The gastroparesis, pancreatitis, gallbladder, and muscle-loss claims have real evidence behind them. The vision loss stat is the most alarming and also the most misrepresented.

On gastroparesis: a 2023 study by Sodhi et al. in JAMA found GLP-1 users had significantly higher rates of gastroparesis compared to non-GLP-1 weight-loss drug users. That is real. On the optic nerve claim: she says users have "a seven times higher risk of a stroke of the optic nerve." That figure comes from a Harvard-affiliated study by Hathaway et al., 2024, published in JAMA Ophthalmology, which found a roughly 4-fold increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in semaglutide users with diabetes, not a 7-fold risk, and not in the general GLP-1 population. On muscle loss: she cites "the Landsat," almost certainly The Lancet. A 2024 paper by Wilding et al. and related analyses of tirzepatide trials did show higher lean mass loss compared to diet alone, though researchers debate whether this is disproportionate or expected with rapid weight loss of any kind.

What did they get wrong (or right)?

The biggest error is the vision loss statistic. "Seven times higher risk" is not what the study found. The Hathaway et al. 2024 JAMA Ophthalmology study reported roughly a 4-fold increased risk of NAION in semaglutide users who had type 2 diabetes, and about a 3.5-fold risk in those with obesity, compared to users of other medications. NAION is also rare to begin with, so even a multiplied risk translates to a small absolute number. Saying "some people are going blind" without that context is a significant overstatement.

She also calls "the Landsat" as a source for muscle loss. That is almost certainly a speech-to-text error for The Lancet, which undermines confidence in how carefully the underlying research was reviewed. The muscle loss finding is real and worth discussing, but the journal name matters when you are presenting yourself as an educational resource.

What she got right: gastroparesis is a documented and serious risk. Pancreatitis is listed in FDA labeling. Gallbladder disease requiring surgery is a known adverse event, supported by clinical trial data. The lawsuit count and the federal MDL (multidistrict litigation) consolidation are consistent with public court records as of early 2024.

What should you actually know?

If you are on a GLP-1 medication, do not stop taking it because of a TikTok. That said, these are not consequence-free drugs, and the risks she names are not fabricated.

The FDA labeling for semaglutide and tirzepatide already includes warnings for pancreatitis, gallbladder disease, and acute kidney injury. Gastroparesis is an emerging concern that has prompted label updates. The optic nerve risk is real enough that the American Academy of Ophthalmology issued guidance in 2024 recommending discussion with patients who have risk factors for NAION.

The "nearly 500 deaths" figure refers to reports in the FDA Adverse Event Reporting System (FAERS). FAERS data is not causal. Anyone can submit a report, and a death that occurs while someone is on a drug does not mean the drug caused it. That number is not meaningless, but presenting it without that caveat is misleading. Millions of people use these drugs. Context is doing a lot of work here, and she did not do that work.

Talk to a prescribing clinician about your personal risk profile. That is, genuinely, the right takeaway from this video.